Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Apr;19(4):220.
doi: 10.1038/s41571-022-00613-5.

Benefit with cemiplimab in cervical cancer

Diana Romero  1
Affiliations
Comment

Benefit with cemiplimab in cervical cancer

Diana Romero. Nat Rev Clin Oncol. 2022 Apr.
No abstract available

PubMed Disclaimer

Comment on

  • Survival with Cemiplimab in Recurrent Cervical Cancer.
    Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.

References

Original article
    1. Tewari, K. S. et al. Survival with cemiplimab in recurrent cervical cancer. N. Engl. J. Med. 386, 544–555 (2022) - DOI

Substances